All In Biotech

Drug Trial Radar · NCT01305408

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Last checked: Nov 20, 2026Latest source record: May 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 399 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

399

Actual

Start

Mar 2011

Primary completion

Jul 2013

Study completion Jul 2013

Sponsor

Lead sponsor
CephalonIndustry
Sponsor type
Industry
First posted
Feb 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.

Conditions

  • Depression

Interventions

  • ArmodafinilDrug

    Armodafinil tablets, taken orally, once daily in the morning

  • PlaceboDrug

    Matching placebo tablets, taken orally, once daily in the morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)Time frame: Day 0 (baseline), Week 8

Locations

130 sites in 14 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 225

    Birmingham, Alabama

  • Teva Investigational Site 295

    Sherman Oaks, California

  • Teva Investigational Site 122

    Temecula, California

  • Teva Investigational Site 606

    Jacksonville Beach, Florida

  • Teva Investigational Site 127

    Lauderhill, Florida

  • Teva Investigational Site 608

    Tampa, Florida

  • Teva Investigational Site 116

    Atlanta, Georgia

  • Teva Investigational Site 205

    Atlanta, Georgia

  • Teva Investigational Site 195

    Park Ridge, Illinois

  • Teva Investigational Site 611

    Indianapolis, Indiana

  • Teva Investigational Site 600

    Lafayette, Indiana

  • Teva Investigational Site 603

    Watertown, Massachusetts

  • Teva Investigational Site 207

    Brooklyn, New York

  • Teva Investigational Site 202

    New York, New York

  • Teva Investigational Site 110

    Staten Island, New York

  • Teva Investigational Site 411

    Staten Island, New York

  • Teva Investigational Site 614

    Wilmington, North Carolina

  • Teva Investigational Site 610

    Cincinnati, Ohio

  • Teva Investigational Site 615

    Toledo, Ohio

  • Teva Investigational Site 401

    Oklahoma City, Oklahoma

  • Teva Investigational Site 609

    Oklahoma City, Oklahoma

  • Teva Investigational Site 616

    Oklahoma City, Oklahoma

  • Teva Investigational Site 406

    Allentown, Pennsylvania

  • Teva Investigational Site 403

    DeSoto, Texas

  • Teva Investigational Site 612

    Friendswood, Texas

  • Teva Investigational Site 408

    Salt Lake City, Utah

  • Teva Investigational Site 613

    Kirkland, Washington

  • Teva Investigational Site 605

    Spokane, Washington

  • Teva Investigational Site 134

    Buenos Aires, Argentina

  • Teva Investigational Site 136

    Buenos Aires, Argentina

  • Teva Investigational Site 881

    Buenos Aires, Argentina

  • Teva Investigational Site 884

    Buenos Aires, Argentina

  • Teva Investigational Site 888

    Buenos Aires, Argentina

  • Teva Investigational Site 236

    Córdoba, Argentina

  • Teva Investigational Site 135

    Córdoba Capital, Argentina

  • Teva Investigational Site 371

    La Plata, Argentina

  • Teva Investigational Site 886

    La Plata, Argentina

  • Teva Investigational Site 138

    La Plata, Buenos Aires, Argentina

  • Teva Investigational Site 882

    Mendoza, Argentina

  • Teva Investigational Site 883

    Mendoza, Argentina

Showing 40 of 130 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.